“…SGAs have been increasingly prescribed for offlabel conditions such as anxiety, attention deficit hyperactivity disorder (ADHD), insomnia and chemotherapy-induced nausea (Maher et al, 2011;Pringsheim and Gardner, 2014;Devlin and Panagiotopoulos, 2015;Bun et al, 2017;Chelkeba et al, 2017). SGAs, such as olanzapine (OLZ), have numerous metabolic side effects (Newcomer, 2005).…”